Lite Strategy, Inc. (LITS)
NASDAQ: LITS · Real-Time Price · USD
1.300
+0.020 (1.56%)
At close: Sep 22, 2026, 4:00 PM EDT
1.350
+0.050 (3.85%)
After-hours: Sep 22, 2026, 7:54 PM EDT
Lite Strategy Employees
Lite Strategy had 4 employees as of June 30, 2025. The number of employees decreased by 24 or -85.71% compared to the previous year.
Employees
4
Change (1Y)
-24
Growth (1Y)
-85.71%
Revenue / Employee
n/a
Profits / Employee
-$15,205,000
Market Cap
44.23M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 4 | -24 | -85.71% |
| Jun 30, 2024 | 28 | -18 | -39.13% |
| Jun 30, 2023 | 46 | -56 | -54.90% |
| Jun 30, 2022 | 102 | 26 | 34.21% |
| Jun 30, 2021 | 76 | 25 | 49.02% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Celularity | 115 |
| Metagenomi Therapeutics | 113 |
| Seres Therapeutics | 66 |
| aTyr Pharma | 60 |
| Actinium Pharmaceuticals | 27 |
| Veru Inc. | 20 |
| Filana Therapeutics | 20 |
LITS News
- 12 days ago - Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York - GlobeNewsWire
- 7 weeks ago - Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share - GlobeNewsWire
- 1 month ago - Lite Strategy Slides: Investor presentation - Filings
- 3 months ago - Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam - GlobeNewsWire
- 3 months ago - Lite Strategy leads strategic investment in LitVM - TheFly
- 3 months ago - Lite Strategy Leads Strategic Investment in LitVM - GlobeNewsWire
- 4 months ago - Lite Strategy Reports Fiscal 2026 Third Quarter Results - GlobeNewsWire
- 4 months ago - Lite Strategy Quarterly report: Q3 2026 - Filings